- Home
- NSIT vs ABCL Comparison
NSIT vs ABCL Comparison
Compare NSIT & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NSIT | ABCL |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.5B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NSIT | ABCL |
|---|---|---|
| Price | $148.14 | $11.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $116.25 | $8.40 |
| AVG Volume (30 Days) | 422.3K | ★ 8.2M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ 3.53 | N/A |
| Revenue | ★ $8,247,180,000.00 | $75,128,000.00 |
| Revenue This Year | $3.79 | N/A |
| Revenue Next Year | $2.16 | $21.85 |
| P/E Ratio | $42.28 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $63.62 | $2.75 |
| 52 Week High | $157.35 | $11.65 |
Technical Indicators
Market Signals| Indicator | NSIT | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 64.71 | 82.08 |
| Support Level | $107.47 | $3.38 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 6.66 | 0.83 |
| MACD | -0.08 | 0.52 |
| Stochastic Oscillator | 69.08 | 98.62 |
Price Performance
Historical ComparisonAbout NSIT Insight Enterprises Inc.
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, government agencies, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital workplace, cloud/data center transformation, IT modernization, Cyber Security and supply chain optimization solutions and services.
About ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.